Business
Director's Dealing
Director's Dealing.
About this update from Valirx Plc
[{"type":"text","content":"\n RNS Number : 7377Z ValiRx PLC 23 July 2008 \n \n\n\nValiRx plc\n\nDirector's dealing\n\n23 July 2008, London. ValiRx plc (AIM:VAL, 'ValiRx') the cancer therapeutics and diagnostics company, announces that on 21 July 2008 Kevin Alexander received 266,666 existing warrants over ordinary shares of 6p each in the Company ('Ordinary Shares'), exercisable at 10p per share, in lieu of services provided.\n\nKevin Alexander is interested, in aggregate, in 543,750 ordinary shares of 6p each in the Company, representing 1.03% of the current issued share capital of the Company, together with a total of 266,666 warrants over ordinary shares.\n\n\nEnquiries: \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nDr. Satu Vainikka\n\n\n\n\n\n\n\nWH Ireland Limited - Nominated Adviser\n\n\nTel: +44 (0) 161 832 2174\n\n\n\n\nDavid Youngman / Adrian Kirk\n\n\n\n\n\n\n\nCollege Hill \n\n\nTel: +44 (0) 20 7457 2020\n\n\n\n\nAdrian Duffield/Justine Lamond\n\n\[email protected] \n\n\n\n\n\nNotes to Editors\n\nAbout ValiRx - www.valirx.com\nValiRx plc (AIM:VAL, 'ValiRx') is a cancer therapeutics and diagnostics company headquartered in London, England and admitted to AIM in October 2006. The Company operates through two subsidiaries, ValiPharma (formerly trading as Cronos Therapeutics) (www.valipharma.com), a UK-based epigenetic drug discovery and development business and ValiBio SA (www.valibio.com), a Belgium-based oncology diagnostics operation.\n\nTherapeutics - ValiPharma\nValiRx utilises a cells own inherent gene control machinery to silence genes involved in cancer cell progression, effectively 'switching off' genes involved in certain forms of cancer through its platform technology GeneICE™ (Gene Inactivation by Chromatin Engineering),. GeneICE™ works through the recruitment of silencing complexes known as Histone Deacetylase Complexes (HDACs) to target genes involved in cancer. ValiRx's lead product VAL 101 targets the anti-apoptotic gene BCL-2 which is over expressed in many cancers including in pancreatic cancer. The Company has also recently expanded its pre-clinical portfolio to include VAL 201 in prostate cancer.\n\nGene silencing technology platform potentially represents an innovative and ground breaking new approach...